RightFit
RecruitingPhase not listed

Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers

An International Multicenter Retrospective Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study reviews past medical records of adults with non-small cell lung cancer (NSCLC) that could be removed by surgery. It compares robot-assisted surgery, video-assisted surgery through small cuts (VATS), and open surgery after treatment with chemotherapy and immune-based drugs, or immune-based drugs alone.

The study is a retrospective observational study. The study is designed to be multicentric and international and it will analyze medical records from selected patients diagnosed with locally advanced and resectable NSCLC who underwent lung resection by robotic, VATS and open approach after receiving neoadjuvant chemo-immunotherapy. There are no risks for the patients, as this is a retrospective data collection.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Were age 18 or older when you had surgery.
  • Had stage IIB or III non-small cell lung cancer that met the study’s tumor and lymph node limits, with no spread to distant parts of the body.
  • Had robot-assisted, video-assisted, or open lung surgery meant to remove all the cancer between January 1, 2016, and March 31, 2024.
  • Before surgery, received chemotherapy plus immunotherapy, or immunotherapy alone. Immunotherapy helps the immune system fight cancer.

Who can't join

  • Were younger than 18 when you had surgery.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Diagnosis of clinical or pathological stage IIB (T1-2, hilar N1, M0) and III (any T, N1-2, M0) NSCLC surgically treated with robotic, VATS and open approach with radical intent from 1st of January 2016 to 31st of March 2024 * Received neoadjuvant chemo-immunotherapy or immunotherapy alone * Age \>= 18 years old at the moment of surgery Exclusion Criteria: * Age \<18 years old at the moment of surgery

Study sites (3)

FL

NY

WV